2012
DOI: 10.1111/j.1523-5378.2012.00981.x
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Helicobacter pylori resistance rates to antibiotics vary in different countries and even in different regions of the same country. Choice of treatment is strongly dependent on antibiotic resistance rates. In some countries, triple therapy with a proton-pump inhibitor, amoxicillin, and clarithromycin is still the best option, but eradication results fall short of what would be desired (90-95%) in countries with clarithromycin resistance >20%, bismuth-containing quadruple therapy, or nonbismuth sequential or con… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
30
2
1

Year Published

2012
2012
2019
2019

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 39 publications
(33 citation statements)
references
References 64 publications
0
30
2
1
Order By: Relevance
“…Sputum amount within 24 h, which is an important marker of disease activity in bronchiectasis, was shown to correlate with the H. pylori immunoglobulin level in the same study. Although these results do not indicate a clear role of H. pylori in the pathogenesis of bronchiectasis, they may suggest a pro-inflammatory role for H. pylori, which may act in concert with other specific factors [61]. In an H. pylori seroprevalence study on patients with bronchial asthma, neither a significant difference between asthmatic patients and the control group was detected, nor was a correlation found between serum H. pylori levels and respiratory functions unlike in 2000, Tsang et al estimated the prevalence of H. pylori infection in a cohort of 90 patients with bronchial asthma.…”
Section: Review Of Literaturecontrasting
confidence: 38%
See 1 more Smart Citation
“…Sputum amount within 24 h, which is an important marker of disease activity in bronchiectasis, was shown to correlate with the H. pylori immunoglobulin level in the same study. Although these results do not indicate a clear role of H. pylori in the pathogenesis of bronchiectasis, they may suggest a pro-inflammatory role for H. pylori, which may act in concert with other specific factors [61]. In an H. pylori seroprevalence study on patients with bronchial asthma, neither a significant difference between asthmatic patients and the control group was detected, nor was a correlation found between serum H. pylori levels and respiratory functions unlike in 2000, Tsang et al estimated the prevalence of H. pylori infection in a cohort of 90 patients with bronchial asthma.…”
Section: Review Of Literaturecontrasting
confidence: 38%
“…Triple therapy should be used in areas where clarithromycin resistance is low (<15 percent). However, when clarithromycin resistance is high (≥15 percent), quadruple therapy should be used to treat H. pylori [52,54,60,61,46].…”
Section: Initial Therapymentioning
confidence: 99%
“…Actualmente la única estrategia de erradicación de la infección es el uso de antibióticos combinados con inhibidores de la secreción de ácido clorhídrico 8 . La eficacia de esos tratamientos ha disminuido conforme ha aparecido resistencia de H.pylori a los diferentes antibióticos 7 , de modo que actualmente alrededor del 20% de los pacientes no consiguen la erradicación tras el manejo inicial y de ellos, alrededor del 24 al 30% continúan sin conseguirla tras un segundo manejo 9,10 .…”
Section: Introductionunclassified
“…The H. pylori-positive patients were allocated into two major study groups, in which they are subdivided according to ABO [29] and Group 2 includes 66 patients received standard H. pylori eradication quadruple regimen (pylera®) containing 140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride (Aptalis Pharma, Canada). In the 10-day quadruple regimen, the three-in-one capsules were taken 4 times daily (after meals and at bedtime) and swallowed whole with 250 mL of water.…”
Section: Study Interventionmentioning
confidence: 99%
“…In some countries, triple therapy with a proton-pump inhibitor, amoxicillin, and clarithromycin is still the best option, and on the other hand, countries with clarithromycin resistance >20%, bismuth-containing quadruple therapy, non-bismuth sequential, or concomitant therapies may be the preferred option [29]. Studies had revealed higher prevalence of H. pylori positive than H. pylori negative among Iraqi population, and in dyspeptic patients, H. pylori prevalence was approximately 74-77% [30,31].…”
Section: Introductionmentioning
confidence: 99%